Cayman CD20 Chimeric Monoclonal Antibody (Clone 10F381 (Rituximab))

CD20 is a non-glycosylated protein encoded by MS4A1 in humans.¹ It is composed of four transmembrane domains, a single intracellular loop, and two extracellular loop domains with both the N- and C-termini located in the cytosol. CD20 is a general B cell marker that is expressed from the late pre-B lymphocyte stage but is not expressed by pro-B lymphocytes and is lost in terminally differentiated plasma cells and plasmablasts. It forms supramolecular complexes with CD53, CD81, and CD82, as well as MHCII, CD40, B cell receptors, and C-terminal Src kinase-binding protein (CBP) to contribute to signal transduction. MS4A1 expression is variable in B cell malignancies, with the lowest expression found in patients with chronic lymphocytic leukemia (CLL) and the highest expression found in patients with diffuse large B cell lymphoma (DLBCL) or hairy cell lymphomas. MS4A1 expression is enriched on IFN-γ-inducible T-box transcription factor-expressing B cells in blood isolated from patients with multiple sclerosis.² Cayman’s CD20 Chimeric Monoclonal (Clone 10F381 (Rituximab)) was produced recombinantly from the original 10F381 antibody sequence and can be used for flow cytometry (FC). The 10F381 antibody was generated by fusing human IgG1κ domains to the antigen-binding domain of a mouse anti-CD20 antibody.³

WARNING This product is not for human or veterinary use.